(Q33335434)
Statements
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies (English)
S G Eckhardt
C D Britten
M Hidalgo
L Siu
L A Hammond
M A Villalona-Calero
S Felton
R Drengler
J G Kuhn
G M Clark
S L Smith
J R MacDonald
C Smith
J Moczygemba
S Weitman
D D Von Hoff